Has Paushak declared dividend?

Paushak Ltd has declared a 200% dividend, amounting to ₹20 per share, with an ex-date of July 26, 2024. While the company shows a positive 5-year total return of 104.37%, shorter-term returns have been negative, reflecting mixed performance overall.

Paushak Ltd has declared a 200% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 200%<BR>- Amount per share: 20<BR>- Ex-date: 26 Jul 24<BR><BR>Dividend Yield: 0.48%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -18.16%, with a dividend return of 0%, resulting in a total return of -18.16%.<BR><BR>Over the past year, the price return was -14.15%, with a dividend return of 0.36%, leading to a total return of -13.79%.<BR><BR>In the 2-year period, the price return was -35.43%, while the dividend return was 0.53%, culminating in a total return of -34.9%.<BR><BR>For the 3-year period, the price return was -53.5%, with a dividend return of 0.56%, resulting in a total return of -52.94%.<BR><BR>In the last 4 years, the price return was -43.08%, and the dividend return was 0.79%, leading to a total return of -42.29%.<BR><BR>Over the 5-year period, the price return was 102.04%, with a dividend return of 2.33%, resulting in a total return of 104.37%.<BR><BR>Overall, while Paushak Ltd has declared a significant dividend, the total returns over various periods show a mixed performance, with substantial losses in the shorter terms but a positive return over the longer 5-year period.

Who are the peers of the Paushak?

Paushak's peers include Pidilite Industries, SRF, Gujarat Fluoroch, Deepak Nitrite, Himadri Special, Platinum Industries, Valiant Organics, Oriental Aromatics, and Fairchem Organic. In terms of returns, SRF leads with 30.73% over one year, while Paushak has a return of -11.61%.

Peers: The peers of Paushak are Pidilite Inds., SRF, Gujarat Fluoroch, Deepak Nitrite, Himadri Special, Platinum Industr, Valiant Organics, Oriental Aromat., and Fairchem Organic.<BR><BR>Quality Snapshot: Excellent management risk is observed at Deepak Nitrite, while Good management risk is found at Pidilite Inds. and SRF. Average management risk is present at Gujarat Fluoroch, Himadri Special, Platinum Industr, Valiant Organics, Oriental Aromat., Fairchem Organic, and the rest. Growth is Excellent at Deepak Nitrite, Good at Himadri Special, Average at Pidilite Inds., SRF, and Platinum Industr, and Below Average at Gujarat Fluoroch, Paushak, Valiant Organics, Oriental Aromat., Fairchem Organic, and the rest. Capital Structure is Excellent at Pidilite Inds., SRF, Deepak Nitrite, and Fairchem Organic, Good at Gujarat Fluoroch, Himadri Special, and Valiant Organics, and Average at Platinum Industr, Paushak, Oriental Aromat., and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is SRF at 30.73%, while the lowest is Fairchem Organic at -24.83%. Paushak's own 1-year return is -11.61%, which is higher than Fairchem Organic's. Additionally, the peers with negative six-month returns include Deepak Nitrite, Platinum Industr, and Paushak.

Is Paushak overvalued or undervalued?

As of April 9, 2020, Paushak is considered very expensive and overvalued with a PE Ratio of 27.25, elevated compared to industry norms, and has underperformed against the Sensex, declining 11.69% year-to-date while the Sensex gained 5.63%.

As of 9 April 2020, the valuation grade for Paushak has moved from expensive to very expensive, indicating a significant shift in its market perception. The company is currently considered overvalued. Key ratios supporting this conclusion include a PE Ratio of 27.25, an EV to EBITDA of 22.83, and a Price to Book Value of 2.89, all of which are elevated compared to industry norms.<BR><BR>In comparison to its peers, Paushak's valuation stands out as particularly high; for instance, P I Industries has a PE Ratio of 35.59 and Bayer CropScience has a PE Ratio of 43.48, both of which are in the very expensive category, yet they still exceed Paushak's valuation metrics. Additionally, UPL, categorized as attractive, has a PE Ratio of 38.74, further highlighting the disparity. Notably, Paushak has underperformed against the Sensex over various time frames, including a year-to-date decline of 11.69% compared to the Sensex's gain of 5.63%, reinforcing the view that the stock is overvalued.

Who are in the management team of Paushak?

As of March 2022, the management team of Paushak includes Chirayu R Amin (Chairman), Udit C Amin, Amit M Goradia, Vijay H Gandhi, Abhijit A Joshi (CEO), Atul Patel, Roopa Patel, and Tushar Arvindbhai Shah, overseeing the company's strategic direction and operations.

As of March 2022, the management team of Paushak includes the following members:<BR><BR>1. Chirayu R Amin - Chairman (Non-Executive)<BR>2. Udit C Amin - Non-Executive & Non-Independent Director<BR>3. Amit M Goradia - Non-Executive & Independent Director<BR>4. Vijay H Gandhi - Non-Executive & Independent Director<BR>5. Abhijit A Joshi - Whole Time Director & CEO<BR>6. Atul Patel - Non-Executive & Independent Director<BR>7. Roopa Patel - Independent Director<BR>8. Tushar Arvindbhai Shah - Independent Director<BR><BR>This team is responsible for overseeing the company's strategic direction and operations.

What does Paushak do?

Paushak Ltd is India's largest manufacturer of phosgene-based specialty chemicals, part of the Alembic Group, with a market cap of INR 1,757 Cr and reported net sales of 524 Cr and net profit of 96 Cr for Q1 2025. Key metrics include a P/E ratio of 35.00 and a dividend yield of 0.36%.

Overview:<BR>Paushak Ltd is India's largest Phosgene based specialty chemical manufacturer operating in the specialty chemicals industry within the small-cap market segment.<BR><BR>History:<BR>Established in May 1972, Paushak Ltd is part of the Alembic Group, which has a legacy of over 115 years. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 524 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 96 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 1,757 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 35.00 <BR>Industry P/E: 40 <BR>Dividend Yield: 0.36% <BR>Debt Equity: 0.03 <BR>Return on Equity: 10.61% <BR>Price to Book: 3.79 <BR><BR>Contact Details:<BR>Address: 5th Floor Administration Buidg, Alembic Road Vadodara Gujarat : 390003 <BR>Tel: 91-265-2280550 <BR>Email: paushak.investors@alembic.co.in <BR>Website: http://www.paushak.com

Who are the top shareholders of the Paushak?

The top shareholders of Paushak include Nirayu Limited with 41.15%, individual investors with 25.23%, and three foreign institutional investors holding 0.01%. There are no mutual funds or public shareholders among the top holdings.

The top shareholders of Paushak include the promoters, with Nirayu Limited holding the largest stake at 41.15%. Additionally, individual investors collectively own 25.23% of the company. There are also three foreign institutional investors (FIIs) that hold a very small percentage, specifically 0.01%. Notably, there are no mutual funds currently invested in Paushak, and there are no public shareholders listed among the top holdings.

How big is Paushak?

As of 24th July, Paushak Ltd has a market capitalization of 1,677.00 Cr, with recent net sales of 210.94 Cr and a net profit of 49.37 Cr. The company has shareholder's funds of 465.49 Cr and total assets of 571.98 Cr.

As of 24th July, Paushak Ltd has a market capitalization of 1,677.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Paushak reported Net Sales of 210.94 Cr and a Net Profit of 49.37 Cr.<BR><BR>For the reporting period of March 2025, the company has Shareholder's Funds amounting to 465.49 Cr and Total Assets of 571.98 Cr.

When is the next results date for Paushak?

The next results date for Paushak is 07 November 2025.

The next results date for Paushak is scheduled for 07 November 2025.

Are Paushak latest results good or bad?

Paushak's latest results are concerning, with a 28.44% decline in net profit and a significant drop in operating profit margin to 25.18%. This indicates challenges in profitability and operational efficiency, suggesting investors should be cautious.

Paushak's latest results indicate a concerning trend for the company. While revenue grew modestly by 5.19% quarter-on-quarter to ₹58.78 crores, net profit saw a significant decline of 28.44% from the previous quarter, dropping to ₹8.61 crores. This marks a 39.37% decrease year-on-year, highlighting a troubling operational environment.<BR><BR>The operating profit margin, excluding other income, fell sharply to 25.18%, the lowest level in seven quarters, down from 31.94% in the previous quarter. This margin compression suggests challenges related to raw material costs or pricing pressures that the company has struggled to manage effectively.<BR><BR>Overall, the results reflect a company facing significant operational headwinds, with declining profitability and weakened margins, which raises concerns about its future performance and ability to navigate competitive dynamics in the specialty chemicals sector. Investors may want to approach with caution until there are signs of recovery in operational metrics.

Should I buy, sell or hold Paushak?

How has been the historical performance of Paushak?

Paushak's historical performance shows a slight decline in net sales and operating profit from Mar'23 to Mar'25, with profit after tax decreasing to 49.38 Cr. Despite increased total assets, rising liabilities and decreased cash flow from operating activities indicate potential liquidity challenges.

Answer:<BR>The historical performance of Paushak shows a fluctuating trend in net sales, with a peak of 212.35 Cr in Mar'23, followed by a slight decline to 210.95 Cr in Mar'25. The total operating income has mirrored this trend, reaching 212.35 Cr in Mar'23 and settling at 210.95 Cr in Mar'25. Raw material costs have decreased from 48.24 Cr in Mar'23 to 43.43 Cr in Mar'25, while employee costs have risen from 26.77 Cr in Mar'23 to 35.48 Cr in Mar'25. Operating profit (PBDIT) has shown a decline from 84.24 Cr in Mar'23 to 73.89 Cr in Mar'25, with the operating profit margin decreasing from 35.41% to 28.28%. Profit before tax also decreased from 72.22 Cr in Mar'23 to 58.78 Cr in Mar'25, leading to a profit after tax of 49.38 Cr in Mar'25, down from 54.01 Cr in Mar'23. The company's total assets have increased from 414.74 Cr in Mar'23 to 571.98 Cr in Mar'25, while total liabilities have also risen from 481.35 Cr to 571.98 Cr in the same period. Cash flow from operating activities has decreased from 56.00 Cr in Mar'24 to 37.00 Cr in Mar'25, indicating a tightening cash position.<BR><BR>Breakdown:<BR>Paushak's net sales have shown a slight decline from 212.35 Cr in Mar'23 to 210.95 Cr in Mar'25, while total operating income has followed a similar pattern. Raw material costs decreased significantly, contributing to a lower operating profit (PBDIT) of 73.89 Cr in Mar'25 compared to 84.24 Cr in Mar'23. The operating profit margin has also decreased, reflecting rising employee costs. Profit before tax has decreased to 58.78 Cr in Mar'25 from 72.22 Cr in Mar'23, resulting in a profit after tax of 49.38 Cr. The company's total assets have increased substantially, indicating growth, but total liabilities have risen correspondingly, suggesting increased financial obligations. Cash flow from operating activities has decreased, highlighting potential liquidity challenges.

Is Paushak technically bullish or bearish?

As of December 1, 2025, the trend is mildly bullish with daily moving averages supporting this view, but caution is advised due to bearish signals from the weekly MACD and Bollinger Bands, despite some bullish indicators in the monthly MACD.

As of 1 December 2025, the technical trend has changed from sideways to mildly bullish. The current stance is mildly bullish, supported by the daily moving averages indicating a positive trend. However, the weekly MACD remains bearish, which suggests caution. The monthly MACD is mildly bullish, providing some support for the overall bullish outlook. The Bollinger Bands are bearish across both weekly and monthly time frames, indicating potential volatility. The KST shows a mixed picture with weekly mildly bearish and monthly mildly bullish readings. Overall, while there are some bullish indicators, the presence of bearish signals in the MACD and Bollinger Bands suggests a cautious approach.

Which are the latest news on Paushak?

Why is Paushak falling/rising?

As of 04-Dec, Paushak Ltd's stock price is at 572.50, down -1.4 (-0.24%), continuing a downward trend with a -23.42% drop over the past month and significant underperformance compared to its sector and benchmark indices. The stock is trading below its moving averages, indicating a bearish trend, and has reported poor financial growth metrics, contributing to its decline.

As of 04-Dec, Paushak Ltd's stock price is falling, currently at 572.50, reflecting a change of -1.4 (-0.24%). The stock has been on a downward trend, having lost -7.55% over the last four days, and it has underperformed its sector by -1.07% today. <BR><BR>In terms of longer-term performance, the stock has shown significant declines, with a -23.42% drop over the past month and a -44.28% decrease over the last three years. This consistent underperformance is highlighted by the fact that it has generated -8.87% returns in the past year while also underperforming the benchmark indices, such as the Sensex, in each of the last three annual periods.<BR><BR>Additionally, the stock is trading below its moving averages across various time frames, indicating a bearish trend. Investor participation has also declined, with delivery volume falling by -25.81% compared to the five-day average. <BR><BR>Financially, the company has reported poor growth metrics, with net sales growing at an annual rate of only 10.81% and operating profit at 4.95% over the last five years. The recent quarterly results showed a significant drop in profit after tax (PAT) by -32.6% compared to the previous four-quarter average, alongside the lowest operating cash flow in recent years. The stock is considered to have a very expensive valuation relative to its peers, trading at a premium despite its declining profits, which have fallen by -19.3% over the past year.<BR><BR>Overall, these factors contribute to the stock's decline, reflecting a combination of poor financial performance, reduced investor interest, and a lack of growth prospects.